MA32460B1 - Derives d'azacarbolines, leur preparation et leur utilisation therapeutique en tant qu'inhibiteurs de kinases - Google Patents

Derives d'azacarbolines, leur preparation et leur utilisation therapeutique en tant qu'inhibiteurs de kinases

Info

Publication number
MA32460B1
MA32460B1 MA33499A MA33499A MA32460B1 MA 32460 B1 MA32460 B1 MA 32460B1 MA 33499 A MA33499 A MA 33499A MA 33499 A MA33499 A MA 33499A MA 32460 B1 MA32460 B1 MA 32460B1
Authority
MA
Morocco
Prior art keywords
substituted
optionally
heterocyclic
branched
straight
Prior art date
Application number
MA33499A
Other languages
Arabic (ar)
English (en)
Inventor
Olivier Bedel
Christopher Arendt
Didier Babin
Thierry Gouyon
Mikhail Levit
Serge Mignani
Neil Moorcroft
David Papin
Ronghua Li
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of MA32460B1 publication Critical patent/MA32460B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)

Abstract

Nouvelles azacarbolines de formule :(i) dans laquelle : r3, r4 représentent indépendamment l'un de l'autre h;hal; cf3; oxy substituée; alkoxy éventuellement substitué; amino éventuellement substitué; carbonyle substitué; carboxyle éventuellement substitué; amide éventuellement substitué; soufre tels que les sulfures, sulfoxides ou sulfones éventuellement substitués;c1-c10 alkyle linéaire, ramifié ou cyclique comportant éventuellement un hétéroatome éventuellement substitué;c2-c7 alkenyle linéaire, ramifié ou cyclique éventuellement substitué; c2-c6 alkynyle linéaire ou ramifié éventuellement substitué; aryle ou hétéroaryle éventuellement substitué;hétérocycloalkyle éventuellement substitué; r6 représente hétéroaryle, c(o)nr1ar1b, hétérocycloalkyle ou -c(o)hétérocycloalkyle tous éventuellement substitués; à l'état de base ou de sel d'addition à un acide. Utilisation en thérapeutique pour le traitement du cancer et procédés de synthèse.
MA33499A 2008-06-12 2011-01-07 Derives d'azacarbolines, leur preparation et leur utilisation therapeutique en tant qu'inhibiteurs de kinases MA32460B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0803262 2008-06-12
PCT/FR2009/051100 WO2009150381A2 (fr) 2008-06-12 2009-06-11 Derives d'azacarbolines, leur preparation et leur utilisation therapeutique

Publications (1)

Publication Number Publication Date
MA32460B1 true MA32460B1 (fr) 2011-07-03

Family

ID=40445526

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33499A MA32460B1 (fr) 2008-06-12 2011-01-07 Derives d'azacarbolines, leur preparation et leur utilisation therapeutique en tant qu'inhibiteurs de kinases

Country Status (26)

Country Link
US (1) US20110178053A1 (fr)
EP (1) EP2303882A2 (fr)
JP (1) JP2011522867A (fr)
KR (1) KR20110016998A (fr)
CN (1) CN102124007A (fr)
AR (1) AR072084A1 (fr)
AU (1) AU2009259114B2 (fr)
BR (1) BRPI0915204A2 (fr)
CA (1) CA2725093A1 (fr)
CO (1) CO6280536A2 (fr)
CR (1) CR11814A (fr)
DO (1) DOP2010000366A (fr)
EA (1) EA018945B1 (fr)
EC (1) ECSP10010670A (fr)
IL (1) IL209840A0 (fr)
MA (1) MA32460B1 (fr)
MX (1) MX2010013699A (fr)
NI (1) NI201000210A (fr)
NZ (1) NZ589839A (fr)
PE (1) PE20110122A1 (fr)
SV (1) SV2010003754A (fr)
TW (1) TW201002711A (fr)
UA (1) UA101668C2 (fr)
UY (1) UY31895A (fr)
WO (1) WO2009150381A2 (fr)
ZA (1) ZA201008387B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009151598A1 (fr) * 2008-06-11 2009-12-17 Genentech, Inc. Diazacarbazoles et procédés d’utilisation
CN102118969B (zh) 2008-06-12 2017-03-08 詹森药业有限公司 组胺h4受体的二氨基吡啶、二氨基嘧啶和二氨基哒嗪调节剂
CN102365282A (zh) * 2009-03-24 2012-02-29 赛诺菲 9H-吡咯并[2，3-b：5，4-c’]二吡啶氮杂咔啉衍生物、其制备方法及其治疗用途
FR2950891B1 (fr) * 2009-10-06 2012-11-09 Sanofi Aventis Derives d'azacarbolines 9h-pyrrolo[2,3-b:5,4-c']dipyridine, leur preparation et leur utilisation therapeutique
FR2953838B1 (fr) * 2009-12-10 2012-02-24 Sanofi Aventis Derives de 9h-beta-carboline (ou 9h-pyridino[3,4-b]indole) trisubstitues, leur preparation et leur utilisation therapeutique
US20110183938A1 (en) * 2009-12-16 2011-07-28 Genentech, Inc. 1,7-diazacarbazoles and methods of use
US9611267B2 (en) 2012-06-13 2017-04-04 Incyte Holdings Corporation Substituted tricyclic compounds as FGFR inhibitors
EP2970312B1 (fr) * 2013-03-11 2017-11-15 The Regents of The University of Michigan Inhibiteurs de bromodomaines bet et méthodes thérapeutiques les utilisant
KR101612179B1 (ko) * 2013-04-19 2016-04-12 영남대학교 산학협력단 아미도피리딘올 유도체 또는 이의 약제학적 허용가능한 염을 유효성분으로 함유하는 암질환 예방 또는 치료용 약학조성물
CN103408573B (zh) * 2013-07-12 2015-12-23 上海工程技术大学 硼酸衍生物及其制备方法和应用
WO2018137655A1 (fr) * 2017-01-25 2018-08-02 江苏豪森药业集团有限公司 Dérivé de pyrrolo-pyridine n-oxyde, son procédé de préparation et son utilisation
KR102700664B1 (ko) * 2017-08-07 2024-08-29 조인트 스탁 컴퍼니 “바이오케드” Cdk8/19 저해제로서 새로운 헤테로사이클릭 화합물
TW201946630A (zh) 2018-05-04 2019-12-16 美商英塞特公司 Fgfr抑制劑之鹽
ES2991427T3 (es) 2018-05-04 2024-12-03 Incyte Corp Formas sólidas de un inhibidor de FGFR y procedimientos para preparar las mismas
WO2020072675A1 (fr) 2018-10-02 2020-04-09 Northwestern University Bêta-carbolines servant de modulateurs allostériques positifs du récepteur humain de la sérotonine 2c (5-ht2c)
AU2020395185A1 (en) 2019-12-04 2022-06-02 Incyte Corporation Derivatives of an FGFR inhibitor
CN116693449A (zh) 2022-03-04 2023-09-05 上海致根医药科技有限公司 用作tyk2抑制剂的化合物、其制备方法及其在医药上的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8119655B2 (en) * 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
WO2009151598A1 (fr) * 2008-06-11 2009-12-17 Genentech, Inc. Diazacarbazoles et procédés d’utilisation

Also Published As

Publication number Publication date
BRPI0915204A2 (pt) 2019-01-15
EA018945B1 (ru) 2013-11-29
KR20110016998A (ko) 2011-02-18
PE20110122A1 (es) 2011-03-07
CR11814A (es) 2011-01-10
WO2009150381A2 (fr) 2009-12-17
CN102124007A (zh) 2011-07-13
NI201000210A (es) 2011-05-09
TW201002711A (en) 2010-01-16
UA101668C2 (ru) 2013-04-25
WO2009150381A3 (fr) 2010-02-18
JP2011522867A (ja) 2011-08-04
EA201170002A1 (ru) 2011-08-30
MX2010013699A (es) 2011-02-23
CO6280536A2 (es) 2011-05-20
AU2009259114A1 (en) 2009-12-17
ZA201008387B (en) 2012-02-29
ECSP10010670A (es) 2011-01-31
EP2303882A2 (fr) 2011-04-06
IL209840A0 (en) 2011-02-28
US20110178053A1 (en) 2011-07-21
AR072084A1 (es) 2010-08-04
CA2725093A1 (fr) 2009-12-17
DOP2010000366A (es) 2010-12-31
AU2009259114B2 (en) 2013-05-23
UY31895A (es) 2010-01-29
SV2010003754A (es) 2011-03-15
NZ589839A (en) 2012-07-27

Similar Documents

Publication Publication Date Title
MA32460B1 (fr) Derives d'azacarbolines, leur preparation et leur utilisation therapeutique en tant qu'inhibiteurs de kinases
UA95976C2 (en) 2-ARYL-6-PHENYLIMIDAZO[1,2-b]PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF
ATE540037T1 (de) Triazolopyridine als phosphodiesterasehemmer zur behandlung von hautkrankheiten
CY1122610T1 (el) Αλκοξυ πυραζολια ως ενεργοποιητες διαλυτης γουανυλικης κυκλασης
CY1118340T1 (el) Αναστολεις κινασης
MY177250A (en) Novel nicotinamide derivative or salt thereof
PE20091819A1 (es) DERIVADOS POLISUSTITUIDOS DE 2-HETEROARIL-6-FENIL-IMIDAZO[1,2-a] PIRIDINAS, SU PREPARACION Y SU APLIACION EN TERAPEUTICA
EA200970149A1 (ru) Производные n-(аминогетероарил)-1h-индол-2-карбоксамидов, их получение и их применение в терапии
EA201300200A1 (ru) N-((6-аминопиридин-3-ил)метил)гетероарилкарбоксамиды в качестве ингибиторов калликреина в плазме
NZ607794A (en) N-acylsulfonamide apoptosis promoters
SMP201100019B (it) Composti organici
AR087995A1 (es) Derivados de n-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}fenil)-n-(4-fluorofenil)ciclopropan-1,1-dicarboxamida
EA201001682A1 (ru) Производные фенил- и бензодиоксинилзамещенных индазолов
EA201391629A1 (ru) Ингибиторы цсж-1r для лечения опухолей головного мозга
EA201001455A1 (ru) Пиридины и пиразины в качестве ингибиторов pi3k (фосфатидилинозиткиназы-3)
EA201590371A1 (ru) 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний
EA201001669A1 (ru) Замещенные пиримидин-5-карбоксамиды 281
DK2840080T3 (da) Nitrogenholdig heterocyklisk forbindelse eller salt deraf
MX348422B (es) Inhibidores de arginasa y sus aplicaciones terapeuticas.
EA201391486A1 (ru) Способы и композиции для лечения болезни паркинсона
EA201491820A1 (ru) Новые тиенопиримидиновые производные, способы их получения и их терапевтические применения
EA201070424A1 (ru) Хиназолиндионовые производные, их получение и их применения в терапии
MX341341B (es) Derivados de benzamida y su uso como inhibidores de proteina de choque termico 90 kda (hsp90).
EA201490630A1 (ru) 6-замещенные 3-(хинолин-6-илтио)[1,2,4]триазоло[4,3-a]пиридины в качестве ингибиторов c-met тирозинкиназы
DK1885187T3 (da) Fremgangsmåde til behandling af lægemiddelresistent cancer